279 related articles for article (PubMed ID: 15598977)
21. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
Panel de expertos de Gesida y Plan Nacional sobre el Sida
Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124
[TBL] [Abstract][Full Text] [Related]
22. A multicenter phase II study of the intravenous administration of liposomal tretinoin in patients with acquired immunodeficiency syndrome-associated Kaposi's sarcoma.
Bernstein ZP; Chanan-Khan A; Miller KC; Northfelt DW; Lopez-Berestein G; Gill PS
Cancer; 2002 Dec; 95(12):2555-61. PubMed ID: 12467070
[TBL] [Abstract][Full Text] [Related]
23. Management of AIDS-related Kaposi's sarcoma: advances in target discovery and treatment.
Dezube BJ
Expert Rev Anticancer Ther; 2002 Apr; 2(2):193-200. PubMed ID: 12113241
[TBL] [Abstract][Full Text] [Related]
24. [Kaposi's sarcoma during HIV infection in Morocco (apropos of 50 cases)].
Chakib A; Hliwa W; Marih L; Himmich H
Bull Soc Pathol Exot; 2003 May; 96(2):86-9. PubMed ID: 12836521
[TBL] [Abstract][Full Text] [Related]
25. Epidemiology of Kaposi's sarcoma in patients with acquired immunodeficiency syndrome in São Paulo, Brazil.
Yoshioka MC; Alchorne MM; Porro AM; Tomimori-Yamashita J
Int J Dermatol; 2004 Sep; 43(9):643-7. PubMed ID: 15357742
[TBL] [Abstract][Full Text] [Related]
26. The virologic, immunologic, and clinical effects of interleukin 2 with potent antiretroviral therapy in patients with moderately advanced human immunodeficiency virus infection: a randomized controlled clinical trial--AIDS Clinical Trials Group 328.
Mitsuyasu R; Gelman R; Cherng DW; Landay A; Fahey J; Reichman R; Erice A; Bucy RP; Kilby JM; Lederman MM; Hamilton CD; Lertora J; White BL; Tebas P; Duliege AM; Pollard RB;
Arch Intern Med; 2007 Mar; 167(6):597-605. PubMed ID: 17389292
[TBL] [Abstract][Full Text] [Related]
27. Interruption of antiretroviral treatment in HIV-infected patients with preserved immune function is associated with a low rate of clinical progression: a prospective study by AIDS Clinical Trials Group 5170.
Skiest DJ; Su Z; Havlir DV; Robertson KR; Coombs RW; Cain P; Peterson T; Krambrink A; Jahed N; McMahon D; Margolis DM;
J Infect Dis; 2007 May; 195(10):1426-36. PubMed ID: 17436222
[TBL] [Abstract][Full Text] [Related]
28. AIDS-related Kaposi's sarcoma: a phase II study of liposomal doxorubicin. The TLC D-99 Study Group.
Cheung TW; Remick SC; Azarnia N; Proper JA; Barrueco JR; Dezube BJ
Clin Cancer Res; 1999 Nov; 5(11):3432-7. PubMed ID: 10589755
[TBL] [Abstract][Full Text] [Related]
29. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.
Steingrover R; Pogány K; Fernandez Garcia E; Jurriaans S; Brinkman K; Schuitemaker H; Miedema F; Lange JM; Prins JM
AIDS; 2008 Aug; 22(13):1583-8. PubMed ID: 18670217
[TBL] [Abstract][Full Text] [Related]
30. Clinical outcomes and immune reconstitution in 103 advanced AIDS patients undergoing 12-month highly active antiretroviral therapy.
Dai Y; Qiu ZF; Li TS; Han Y; Zuo LY; Xie J; Ma XJ; Liu ZY; Wang AX
Chin Med J (Engl); 2006 Oct; 119(20):1677-82. PubMed ID: 17097013
[TBL] [Abstract][Full Text] [Related]
31. Acquired immunodeficiency syndrome-related Kaposi's sarcoma regression after highly active antiretroviral therapy: biologic correlates of clinical outcome.
Cattelan AM; Calabrò ML; Gasperini P; Aversa SM; Zanchetta M; Meneghetti F; De Rossi A; Chieco-Bianchi L
J Natl Cancer Inst Monogr; 2001; (28):44-9. PubMed ID: 11158206
[TBL] [Abstract][Full Text] [Related]
32. A community randomized controlled clinical trial of mixed carotenoids and micronutrient supplementation of patients with acquired immunodeficiency syndrome.
Austin J; Singhal N; Voigt R; Smaill F; Gill MJ; Walmsley S; Salit I; Gilmour J; Schlech WF; Choudhri S; Rachlis A; Cohen J; Trottier S; Toma E; Phillips P; Ford PM; Woods R; Singer J; Zarowny DP; Cameron DW;
Eur J Clin Nutr; 2006 Nov; 60(11):1266-76. PubMed ID: 16721396
[TBL] [Abstract][Full Text] [Related]
33. The effects of human herpesvirus 8 infection and interferon-gamma response in cutaneous lesions of Kaposi sarcoma differ among human immunodeficiency virus-infected and uninfected individuals.
Guedes F; de Andrade HF; Fernandes ER; Tuon FF; Brasil RA; Pagliari C; Duarte MI
Br J Dermatol; 2008 Sep; 159(4):839-46. PubMed ID: 18644020
[TBL] [Abstract][Full Text] [Related]
34. Regression of AIDS-related Kaposi's sarcoma associated with clearance of human herpesvirus-8 from peripheral blood mononuclear cells following initiation of antiretroviral therapy.
Wit FW; Sol CJ; Renwick N; Roos MT; Pals ST; van Leeuwen R; Goudsmit J; Reiss P
AIDS; 1998 Jan; 12(2):218-9. PubMed ID: 9468373
[No Abstract] [Full Text] [Related]
35. Highly active antiretroviral therapy in AIDS-associated Kaposi's sarcoma: implications for the design of therapeutic trials in patients with advanced, symptomatic Kaposi's sarcoma.
Krown SE
J Clin Oncol; 2004 Feb; 22(3):399-402. PubMed ID: 14752065
[No Abstract] [Full Text] [Related]
36. Risk of cancers during interrupted antiretroviral therapy in the SMART study.
Silverberg MJ; Neuhaus J; Bower M; Gey D; Hatzakis A; Henry K; Hidalgo J; Lourtau L; Neaton JD; Tambussi G; Abrams DI
AIDS; 2007 Sep; 21(14):1957-63. PubMed ID: 17721103
[TBL] [Abstract][Full Text] [Related]
37. Intermittent antiretroviral therapy in patients with controlled HIV infection.
Marchou B; Tangre P; Charreau I; Izopet J; Girard PM; May T; Ragnaud JM; Aboulker JP; Molina JM;
AIDS; 2007 Feb; 21(4):457-66. PubMed ID: 17301564
[TBL] [Abstract][Full Text] [Related]
38. Treatment of HIV-1-associated Kaposi's sarcoma with pegylated liposomal doxorubicin and HAART simultaneously induces effective tumor remission and CD4+ T cell recovery.
Lichterfeld M; Qurishi N; Hoffmann C; Hochdorfer B; Brockmeyer NH; Arasteh K; Mauss S; Rockstroh JK;
Infection; 2005 Jun; 33(3):140-7. PubMed ID: 15940415
[TBL] [Abstract][Full Text] [Related]
39. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks.
Cohen SB; Emery P; Greenwald MW; Dougados M; Furie RA; Genovese MC; Keystone EC; Loveless JE; Burmester GR; Cravets MW; Hessey EW; Shaw T; Totoritis MC;
Arthritis Rheum; 2006 Sep; 54(9):2793-806. PubMed ID: 16947627
[TBL] [Abstract][Full Text] [Related]
40. Weekly oral etoposide in patients with Kaposi's sarcoma associated with human immunodeficiency virus infection: a phase I multicenter trial of the AIDS Clinical Trials Group.
Paredes J; Kahn JO; Tong WP; Feldstein ML; Lin S; Bennett JM; Metroka CE; Ratner L; Krown SE
J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Jun; 9(2):138-44. PubMed ID: 7749790
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
